Top

Published in:

01-09-2016 | Review

Multiple roles of CD90 in cancer

Authors: Atul Kumar, Anshuman Bhanja, Jina Bhattacharyya, Bithiah Grace Jaganathan

Published in: Tumor Biology | Issue 9/2016

Abstract

THY1 (CD90) is a 25–37-kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein. It is usually expressed on thymocytes, mesenchymal stem cells, hematopoietic stem cells, natural killer cells, neurons, endothelial cells, renal glomerular mesangial cells, follicular dendritic cells, fibroblasts, and myofibroblasts. It has been found to regulate cell adhesion, migration, apoptosis, axon growth, cell-cell and cell-matrix interactions, T-cell activation, and fibrosis. Several reports have shown that CD90 has an important role in cancer in regulating cancer cell proliferation, metastasis, and angiogenesis. There are also evidences that CD90 is an important prognostic marker in many cancers. Consequently, therapies that target CD90 have great promise in treating many cancers. However, several studies also indicate a contradictory role for CD90, where it acts as a tumor suppressor. In this review, we summarize the expression, function of CD90 in different cancers and its possible use as a biomarker or a therapeutic target in cancer. The challenges and future prospects for the use of CD90 for clinical applications are also discussed in this review.

Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012;19:R187–204.PubMedPubMedCentralCrossRef

Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res. 2012;10:1403–18.PubMedPubMedCentralCrossRef

Pascal LE, Ai J, Vencio RZ, Vencio EF, Zhou Y, Page LS, et al. Differential inductive signaling of cd90 prostate cancer-associated fibroblasts compared to normal tissue stromal mesenchyme cells. Cancer Microenviron. 2011;4:51–9.PubMedPubMedCentralCrossRef

Pascal LE, Goo YA, Vencio RZN, Page LS, Chambers AA, Liebeskind ES, et al. Gene expression down-regulation in cd90(+) prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer. 2009;9.

True LD, Zhang H, Ye ML, Huang CY, Nelson PS, von Haller PD, et al. Cd90/thy1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol. 2010;23:1346–56.PubMedPubMedCentralCrossRef

Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal. 2011;9.

Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY, et al. Therapeutics targeting cd90-integrin-ampk-cd133 signal axis in liver cancer. Oncotarget. 2015;6:42923–37.PubMedPubMedCentral

Ho DWY, Yang ZF, Yi K, Lam CT, Ng MNP, Yu WC, et al. Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One. 2012;7.

Jiang J, Zhang Y, Chuai S, Wang Z, Zheng D, Xu F, et al. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by cd90 phenotype. Oncogene. 2012;31:671–82.PubMedCrossRef

10.

Sukowati CH, Anfuso B, Torre G, Francalanci P, Croce LS, Tiribelli C. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One. 2013;8:e76830.PubMedPubMedCentralCrossRef

11.

Tang KH, Dai YD, Tong M, Chan YP, Kwan PS, Fu L, et al. A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res. 2013;73:2322–32.PubMedCrossRef

12.

Yan XP, Luo H, Zhou XD, Zhu BJ, Wang YL, Bian XW. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep. 2013;30:2733–40.PubMed

13.

Zhu L, Zhang W, Wang J, Liu R. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma. Tumour Biol. 2015;36:5353–60.PubMedCrossRef

14.

Lobba ARM, Forni MF, Carreira ACO, Sogayar MC. Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytometry Part A. 2012;81A:1084–91.CrossRef

15.

Zhu J, Thakolwiboon S, Liu X, Zhang M, Lubman DM. Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. PLoS One. 2014;9:e115507.PubMedPubMedCentralCrossRef

16.

Abeysinghe HR, Pollock SJ, Guckert NL, Veyberman Y, Keng P, Halterman M, et al. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genet Cytogenet. 2004;149:1–10.PubMedCrossRef

17.

Cheng Y, Stanbridge EJ, Kong H, Bengtsson U, Lerman MI, Lung ML. A functional investigation of tumor suppressor gene activities in a nasopharyngeal carcinoma cell line HONE1 using a monochromosome transfer approach. Genes Chromosomes Cancer. 2000;28:82–91.PubMedCrossRef

18.

Zeng L, Peng Z, Zhang M. Construction of THY1 eukaryotic expression plasmid and its effects on growth of ovarian cancer SKOV3 cells. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009;26:620–4.PubMed

19.

Crawford JM, Barton RW. Thy-1 glycoprotein: structure, distribution, and ontogeny. Lab Invest. 1986;54:122–35.PubMed

20.

Seki T, Spurr N, Obata F, Goyert S, Goodfellow P, Silver J. The human Thy-1 gene: structure and chromosomal location. Proc Natl Acad Sci U S A. 1985;82:6657–61.PubMedPubMedCentralCrossRef

21.

Williams AF, Gagnon J. Neuronal cell thy-1 glycoprotein: homology with immunoglobulin. Science. 1982;216:696–703.PubMedCrossRef

22.

Haeryfar SM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker. J Immunol. 2004;173:3581–8.PubMedCrossRef

23.

Pont S. Thy-1: a lymphoid cell subset marker capable of delivering an activation signal to mouse T lymphocytes. Biochimie. 1987;69:315–20.PubMedCrossRef

24.

Barboni E, Rivero BP, George AJT, Martin SR, Renouf DV, Hounsell EF, et al. The glycophosphatidylinositol anchor affects the conformation of Thy-1 protein. J Cell Sci. 1995;108:487–97.PubMed

25.

Kukulansky T, Abramovitch S, Hollander N. Cleavage of the glycosylphosphatidylinositol anchor affects the reactivity of thy-1 with antibodies. J Immunol. 1999;162:5993–7.PubMed

26.

Mayeux-Portas V, File SE, Stewart CL, Morris RJ. Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food. Curr Biol. 2000;10:68–75.PubMedCrossRef

27.

Beissert S, He HT, Hueber AO, Lellouch AC, Metze D, Mehling A, et al. Impaired cutaneous immune responses in Thy-1-deficient mice. J Immunol. 1998;161:5296–302.PubMed

28.

Simon PD, McConnell J, Zurakowski D, Vorwerk CK, Naskar R, Grosskreutz CL, et al. Thy-1 is critical for normal retinal development. Dev Brain Res. 1999;117:219–23.CrossRef

29.

Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol. 2005;167:365–79.PubMedPubMedCentralCrossRef

30.

Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med. 1993;177:1331–42.PubMedCrossRef

31.

Killeen N. T-cell regulation: Thy-1—hiding in full view. Curr Biol. 1997;7:R774–7.PubMedCrossRef

32.

Saalbach A, Kraft R, Herrmann K, Haustein UF, Anderegg U. The monoclonal antibody AS02 recognizes a protein on human fibroblasts being highly homologous to Thy-1. Arch Dermatol Res. 1998;290:360–6.PubMedCrossRef

33.

Saalbach A, Wetzig T, Haustein UF, Anderegg U. Detection of human soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells are a possible source of soluble Thy-1 in serum. Cell Tissue Res. 1999;298:307–15.PubMedCrossRef

34.

Seeger RC, Danon YL, Rayner SA, Hoover F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol. 1982;128:983–9.PubMed

35.

Gunter KC, Germain RN, Kroczek RA, Saito T, Yokoyama WM, Chan C, et al. Thy-1-mediated T-cell activation requires co-expression of CD3/Ti complex. Nature. 1987;326:505–7.PubMedCrossRef

36.

Dreyer EB, Leifer D, Heng JE, McConnell JE, Gorla M, Levin LA, et al. An astrocytic binding site for neuronal Thy-1 and its effect on neurite outgrowth. Proc Natl Acad Sci U S A. 1995;92:11195–9.PubMedPubMedCentralCrossRef

37.

Herrera-Molina R, Frischknecht R, Maldonado H, Seidenbecher CI, Gundelfinger ED, Hetz C, et al. Astrocytic alphavbeta3 integrin inhibits neurite outgrowth and promotes retraction of neuronal processes by clustering Thy-1. PLoS One. 2012;7:e34295.PubMedPubMedCentralCrossRef

38.

Seki M, Nawa H, Morioka T, Fukuchi T, Oite T, Abe H, et al. Establishment of a novel enzyme-linked immunosorbent assay for Thy-1; quantitative assessment of neuronal degeneration. Neurosci Lett. 2002;329:185–8.PubMedCrossRef

39.

Fujita N, Kato Y, Naito M, Tsuruo T. A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Int J Cancer. 1996;66:544–50.PubMedCrossRef

40.

Fujita N, Kodama N, Kato Y, Lee SH, Tsuruo T. Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases. Exp Cell Res. 1997;232:400–6.PubMedCrossRef

41.

Hueber AO, Raposo G, Pierres M, He HT. Thy-1 triggers mouse thymocyte apoptosis through a bcl-2-resistant mechanism. J Exp Med. 1994;179:785–96.PubMedCrossRef

42.

Narisawa-Saito M, Kimura S, Fujiwara N, Oite T, Shimoji K, Shimizu F. Thy-1-mediated phosphatidylinositol turnover in cultured rat glomerular mesangial cell. J Cell Physiol. 1996;168:705–10.PubMedCrossRef

43.

Sato T, van Dixhoorn MG, Schroeijers WE, van Es LA, Daha MR. Efficient induction of apoptosis in cultured rat glomerular mesangial cells by dimeric monoclonal IgA anti-Thy-1 antibodies. Kidney Int. 1997;51:173–81.PubMedCrossRef

44.

Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J. 2006;20:1045–54.PubMedCrossRef

45.

Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta. 1763;2006:991–9.

46.

Saalbach A, Haustein UF, Anderegg U. A ligand of human Thy-1 is localized on polymorphonuclear leukocytes and monocytes and mediates the binding to activated Thy-1-positive microvascular endothelial cells and fibroblasts. J Invest Dermatol. 2000;115:882–8.PubMedCrossRef

47.

Saalbach A, Hildebrandt G, Haustein UF, Anderegg U. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1-positive microvascular endothelial cells. Microvasc Res. 2002;64:86–93.PubMedCrossRef

48.

Rege TA, Pallero MA, Gomez C, Grenett HE, Murphy-Ullrich JE, Hagood JS. Thy-1, via its GPI anchor, modulates Src family kinase and focal adhesion kinase phosphorylation and subcellular localization, and fibroblast migration, in response to thrombospondin-1/hep I. Exp Cell Res. 2006;312:3752–67.PubMedCrossRef

49.

Barker TH, Hagood JS. Getting a grip on Thy-1 signaling. Biochim Biophys Acta. 1793;2009:921–3.

50.

Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RC, Steel CM, et al. Definition and refinement of a region of loss of heterozygosity at 11q23.3–q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 1996;56:950–4.PubMed

51.

Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, et al. Thy1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet. 2003;143:125–32.PubMedCrossRef

52.

Cao Q, Abeysinghe H, Chow O, Xu J, Kaung HL, Fong CT, et al. Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet. 2001;129:131–7.PubMedCrossRef

53.

Abeysinghe HR, Li LQ, Guckert NL, Reeder J, Wang N. Thy-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer. Cancer Genet Cytogenet. 2005;161:151–8.PubMedCrossRef

54.

Akiyama SK, Olden K, Yamada KM. Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995;14:173–89.PubMedCrossRef

55.

Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res. 1996;56:5684–91.PubMed

56.

Zeng LQ, Peng ZL, Duan ZL. Expression of THY1 gene in epithelial ovarian cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:118–20.PubMed

57.

Hui AB, Lo KW, Leung SF, Choi PH, Fong Y, Lee JC, et al. Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res. 1996;56:3225–9.PubMed

58.

Mutirangura A, Tanunyutthawongese C, Pornthanakasem W, Kerekhanjanarong V, Sriuranpong V, Yenrudi S, et al. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. Br J Cancer. 1997;76:770–6.PubMedPubMedCentralCrossRef

59.

Lung HL, Bangarusamy DK, Xie D, Cheung AKL, Cheng Y, Kumaran MK, et al. Thy1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene. 2005;24:6525–32.PubMed

60.

Lung HL, Cheung AKL, Cheng Y, Kwong FM, Lo PHY, Law EWL, et al. Functional characterization of THY1 as a tumor suppressor gene with antiinvasive activity in nasopharyngeal carcinoma. Int J Cancer. 2010;127:304–12.PubMed

61.

Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8:278–92.PubMedCrossRef

62.

Fiegel HC, Kaifi JT, Quaas A, Varol E, Krickhahn A, Metzger R, et al. Lack of Thy1 (CD90) expression in neuroblastomas is correlated with impaired survival. Pediatr Surg Int. 2008;24:101–5.PubMedCrossRef

63.

Piper DR, Mujtaba T, Keyoung H, Roy NS, Goldman SA, Rao MS, et al. Identification and characterization of neuronal precursors and their progeny from human fetal tissue. J Neurosci Res. 2001;66:356–68.PubMedPubMedCentralCrossRef

64.

Uchida N, Buck DW, He DP, Reitsma MJ, Masek M, Phan TV, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A. 2000;97:14720–5.PubMedPubMedCentralCrossRef

65.

Nava S, Westgren M, Jaksch M, Tibell A, Broome U, Ericzon BG, et al. Characterization of cells in the developing human liver. Differentiation. 2005;73:249–60.PubMedCrossRef

66.

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153–66.PubMedCrossRef

67.

Ceafalan L, Vidulescu C, Radu E, Regalia T, Popescu I, Pana M, et al. Expression of stem cell markers on fetal and tumoral human liver cells in primary culture. Rev Med Chir Soc Med Nat Iasi. 2005;109:96–104.PubMed

68.

Cheng BQ, Jiang Y, Li DL, Fan JJ, Ma M. Up-regulation of Thy-1 promotes invasion and metastasis of hepatocarcinomas. Asian Pac J Cancer Prev. 2012;13:1349–53.PubMedCrossRef

69.

Lingala S, Cui YY, Chen XL, Ruebner BH, Qian XF, Zern MA, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010;89:27–35.PubMedPubMedCentralCrossRef

70.

Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJP, Hu RM. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 2011;113:833–8.PubMedCrossRef

71.

Yu XH, Xu LB, Liu C, Zhang R, Wang J. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. Dig Dis Sci. 2011;56:252–9.PubMedCrossRef

72.

Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, et al. Discrete nature of EpCAM+ and CD90+cancer stem cells in human hepatocellular carcinoma. Hepatology. 2013;57:1484–97.PubMedCrossRef

73.

Yang ZF, Ngai P, Ho DW, Yu WC, Ng MNP, Lau CK, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47:919–28.PubMedCrossRef

74.

Cheng BQ, Jiang Y, Zhu Q, Lin WG. Wnt/beta-catenin aids in regulating the proliferation of hepG2 cells mediated by thy-1. Genet Mol Res. 2014;13:5115–27.PubMedCrossRef

75.

Jia Q, Zhang XL, Deng T, Gao J. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Cell Reprogram. 2013;15:143–50.PubMed

76.

Bahnassy AA, Fawzy M, El-Wakil M, Zekri AR, Abdel-Sayed A, Sheta M. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res. 2014;165:396–406.PubMedCrossRef

77.

Furlan A, Vercamer C, Desbiens X, Pourtier A. Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol. 2008;215:782–93.PubMedCrossRef

78.

Taki M, Verschueren K, Yokoyama K, Nagayama M, Kamata N. Involvement of Ets-1 transcription factor in inducing matrix metalloproteinase-2 expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Int J Oncol. 2006;28:487–96.PubMed

79.

Chen JF, Zhang LJ, Zhao AL, Wang Y, Wu N, Xiong HC, et al. [Abnormal expression of Thy-1 as a novel tumor marker in lung cancer and its prognostic significance]. Zhonghua Yi Xue Za Zhi. 2005;85:1921–5.PubMed

80.

Jacob M, Male H, Diaz E, Huang C, Farassati F. CD90 (thy1) as a potential cancer stem cell markers and therapeutic target in non-small cell lung cancer. http://wwwatsjournalsorg/doi/abs/101164/ajrccm-conference20111831_MeetingAbstractsA5070 2011

81.

Hong X, Chedid K, Kalkanis SN. Glioblastoma cell line-derived spheres in serum-containing medium versus serum-free medium: a comparison of cancer stem cell properties. Int J Oncol. 2012;41:1693–700.PubMed

82.

Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008;3.

83.

Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, et al. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer. 2011;104:1410–7.PubMedPubMedCentralCrossRef

84.

Kawamura K, Hiroshima K, Suzuki T, Chai K, Yamaguchi N, Shingyoji M, et al. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry. Am J Clin Pathol. 2013;140:544–9.PubMedCrossRef

85.

Ziegler A, Cerciello F, Bigosch C, Bausch-Fluck D, Felley-Bosco E, Ossola R, et al. Proteomic surfaceome analysis of mesothelioma. Lung Cancer. 2012;75:189–96.PubMedCrossRef

86.

Melotti A, Daga A, Marubbi D, Zunino A, Mutti L, Corte G. In vitro and in vivo characterization of highly purified human mesothelioma derived cells. BMC Cancer. 2010;10.

87.

Frei C, Opitz I, Soltermann A, Fischer B, Moura U, Rehrauer H, et al. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis. 2011;32:1324–32.PubMedCrossRef

88.

He JT, Liu YS, Zhu T, Zhu JH, DiMeco F, Vescovi AL, et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics. 2012;11.

89.

Parry PV, Engh JA. CD90 is identified as a marker for cancer stem cells in high-grade gliomas using tissue microarrays. Neurosurgery. 2012;70:N23–4.PubMedCrossRef

90.

He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics. 2011;11:M111 010744.PubMedPubMedCentralCrossRef

91.

Woo SR, Oh YT, An JY, Kang BG, Nam DH, Joo KM. Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol. 2015;48:44–53.PubMedPubMedCentralCrossRef

92.

Scognamiglio G, D’Antonio A, Rossi G, Cavazza A, Camerlingo R, Pirozzi G, et al. CD90 expression in atypical meningiomas and meningioma metastasis. Am J Clin Pathol. 2014;141:841–9.PubMedCrossRef

93.

Fabi A, Nuzzo C, Vidiri A, Ciccarese M, Felici A, Cattani F, et al. Bone and lung metastases from intracranial meningioma. Anticancer Res. 2006;26:3835–7.PubMed

94.

Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333:218–21.PubMedCrossRef

95.

Kozii R, Wilson J, Persichetti J, Phelps V, Ball SEB, Ball ED. Thy-1 expression on blast cells from adult patients with acute myeloid leukemia. Leuk Res. 1997;21:381–5.PubMedCrossRef

96.

Campos L, Guyotat D. Expression of Thy-1 antigen (CDw90) on adult acute leukemia blast cells. Blood. 1996;87:413–4.PubMed

97.

Petrovici K, Graf M, Reif S, Hecht K, Schmetzer H. Expression profile of the progenitor cell markers CD34, CD38 and CD90 in acute myeloid leukemia and their prognostic significance. J Cancer Mol. 2010;5:79–86.

98.

Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol. 2004;125:203–12.PubMedCrossRef

99.

Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104–12.PubMed

100.

Cascavilla N, Melillo L, D’Arena G, Greco MM, Carella AM, Sajeva MR, et al. Minimally differentiated acute myeloid leukemia (AML M0): clinico-biological findings of 29 cases. Leuk Lymphoma. 2000;37:105–13.PubMedCrossRef

101.

Dohner K, Brown J, Hehmann U, Hetzel C, Stewart J, Lowther G, et al. Molecular cytogenetic characterization of a critical region in bands 7q35–q36 commonly deleted in malignant myeloid disorders. Blood. 1998;92:4031–5.PubMed

102.

Holden JT, Geller RB, Farhi DC, Holland HK, Stempora LL, Phillips CN, et al. Characterization of Thy-1 (CDw90) expression in CD34(+) acute-leukemia. Blood. 1995;86:60–5.PubMed

103.

Wuchter C, Ratei R, Spahn G, Schoch C, Harbott J, Schnittger S, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001;86:154–61.PubMed

104.

Inaba T, Shimazaki C, Sumikuma T, Shimura K, Takahashi R, Hirai H, et al. Flow cytometric analysis of Thy-1 expression in myelodysplastic syndrome. Int J Hematol. 1998;68:403–10.PubMedCrossRef

105.

Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120:2076–86.PubMedPubMedCentralCrossRef

106.

Takahashi T, Mizutani M, Miwa H, Katayama N, Nishii K, Shikami M, et al. Frequent expression of human Thy-1 antigen on pre-b cell acute lymphoblastic leukemia with t(9;22). Int J Hematol. 1998;67:369–78.PubMedCrossRef

107.

Ishiura Y, Kotani N, Yamashita R, Yamamoto H, Kozutsumi Y, Honke K. Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. Biochem Biophys Res Commun. 2010;396:329–34.PubMedCrossRef

108.

Yamazaki H, Nishida H, Iwata S, Dang NH, Morimoto C. CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun. 2009;383:172–7.PubMedCrossRef

109.

Wang X, Liu Y, Zhou K, Zhang G, Wang F, Ren J. Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol. 2015;8:5105–12.PubMedPubMedCentral

110.

Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry Part B-Clinical Cytometry. 2010;78B:287–301.CrossRef

111.

Johansson I, Ringner M, Hedenfalk I. The landscape of candidate driver genes differs between male and female breast cancer. PLoS One. 2013;8.

112.

Jurisic G, Iolyeva M, Proulx ST, Halin C, Detmar M. Thymus cell antigen 1 (Thy1, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. Exp Cell Res. 2010;316:2982–92.PubMedPubMedCentralCrossRef

113.

Schubert K, Gutknecht D, Koberle M, Anderegg U, Saalbach A. Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation. Am J Pathol. 2013;182:266–76.PubMedCrossRef

114.

Ishizu A, Ishikura H, Nakamaru Y, Kikuchi K, Koike T, Yoshiki T. Interleukin-1alpha regulates Thy-1 expression on rat vascular endothelial cells. Microvasc Res. 1997;53:73–8.PubMedCrossRef

115.

Ishizu A, Ishikura H, Nakamaru Y, Takeuchi E, Kimura C, Koike T, et al. Thy-1 induced on rat endothelium regulates vascular permeability at sites of inflammation. Int Immunol. 1995;7:1939–47.PubMedCrossRef

116.

Leyton L, Schneider P, Labra CV, Ruegg C, Hetz CA, Quest AF, et al. Thy-1 binds to integrin beta(3) on astrocytes and triggers formation of focal contact sites. Curr Biol. 2001;11:1028–38.PubMedCrossRef

117.

Saalbach A, Wetzel A, Haustein UF, Sticherling M, Simon JC, Anderegg U. Interaction of human Thy-1 (CD90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene. 2005;24:4710–20.PubMedCrossRef

118.

Zhao HJ, Peehl DM. Tumor-promoting phenotype of CD90(hi) prostate cancer-associated fibroblasts. Prostate. 2009;69:991–1000.PubMedPubMedCentralCrossRef

119.

Tiveron MC, Nosten-Bertrand M, Jani H, Garnett D, Hirst EM, Grosveld F, et al. The mode of anchorage to the cell surface determines both the function and the membrane location of Thy-1 glycoprotein. J Cell Sci. 1994;107(Pt 7):1783–96.PubMed

120.

Narisawa-Saito M, Yamanashi Y, Morioka T, Oite T, Shimizu F. Thy-1 molecule associates with protein tyrosine kinase(s) in rat mesangial cells. Clin Exp Immunol. 1996;106:86–90.PubMedPubMedCentralCrossRef

121.

Thomas PM, Samelson LE. The glycophosphatidylinositol-anchored Thy-1 molecule interacts with the p60fyn protein tyrosine kinase in T cells. J Biol Chem. 1992;267:12317–22.PubMed

122.

Haeryfar SM, Hoskin DW. Selective pharmacological inhibitors reveal differences between Thy-1- and T cell receptor-mediated signal transduction in mouse T lymphocytes. Int Immunopharmacol. 2001;1:689–98.PubMedCrossRef

123.

Koumas L, Phipps RP. Differential COX localization and pg release in Thy-1(+) and Thy-1(−) human female reproductive tract fibroblasts. Am J Physiol Cell Physiol. 2002;283:C599–608.PubMedCrossRef

124.

Ramakrishnan S, Houston LL. Prevention of growth of leukemia-cells in mice by monoclonal-antibodies directed against Thy-1.1 antigen disulfide linked to 2 ribosomal inhibitors—pokeweed antiviral protein or ricin-A chain. Cancer Res. 1984;44:1398–404.PubMed

125.

Colombatti M, Colombatti A, Blythman HE, Bron C. Thy 1.2+ leukemia-cells eradicated from in vitro leukemia-bone marrow cell mixtures by antibody-toxin conjugates. J Natl Cancer Inst. 1984;72:1095–9.PubMed

126.

Badger CC, Krohn KA, Peterson AV, Shulman H, Bernstein ID. Experimental radiotherapy of murine lymphoma with I-131-labeled anti-Thy 1.1 monoclonal-antibody. Cancer Res. 1985;45:1536–44.PubMed

127.

Cheng R, Weissman I, Jones P: Characterization of CD90 as a therapeutic antibody target on cancer stem cells. Stanford Digital Repository 2015

128.

Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood. 2008;111:2211–9.PubMedPubMedCentralCrossRef

129.

Vidal M, Morris R, Grosveld F, Spanopoulou E. Tissue-specific control elements of the Thy-1 gene. EMBO J. 1990;9:833–40.PubMedPubMedCentral

130.

Bradley JS, Ramirez G, Hagood JS. Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. Biofactors. 2009;35:258–65.PubMedCrossRef

131.

Jaganathan BG, Tisato V, Vulliamy T, Dokal I, Marsh J, Dazzi F, et al. Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation. Leukemia. 2010;24:1791–5.PubMedCrossRef

132.

Almqvist P, Carlsson SR. Characterization of a hydrophilic form of Thy-1 purified from human cerebrospinal fluid. J Biol Chem. 1988;263:12709–15.PubMed

Title: Multiple roles of CD90 in cancer
Authors: Atul Kumar
Anshuman Bhanja
Jina Bhattacharyya
Bithiah Grace Jaganathan
Publication date: 01-09-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5112-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention

PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc

The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer

TUSC3 suppresses glioblastoma development by inhibiting Akt signaling

Impact of X-linked inhibitor of apoptosis protein on survival of nasopharyngeal carcinoma patients following radiotherapy

EphA4-mediated signaling regulates the aggressive phenotype of irradiation survivor colorectal cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer